Table 4.
Subgroup analysis for association between TXA and PJI
| Variable | PJI number/ total | PJI rate | Adjust OR | 95%CI | p value |
|---|---|---|---|---|---|
| Overall (n = 8042) | |||||
| No TXA | 94 / 4378 | 2.1% | reference | ||
| With TXA | 39 / 3664 | 1.1% | 0.54 | 0.36–0.80 | 0.002 |
| IV TXA | 24 / 2345 | 1.0% | 0.53 | 0.33–0.84 | 0.007 |
| Topical TXA | 15 / 1319 | 1.1% | 0.51 | 0.29–0.89 | 0.018 |
| IV TXA - Topical TXA | - | 0.96 | 0.50–1.85 | 0.907 | |
| Hip (n = 1766) | |||||
| No TXA | 10 / 797 | 1.3% | reference | ||
| With TXA | 6 / 969 | 0.6% | 0.51 | 0.17–1.47 | 0.209 |
| IV TXA | 6 / 777 | 0.8% | 0.65 | 0.22–1.89 | 0.426 |
| Topical TXA | 0 / 192 | 0% | - | - | 0.995$ |
| IV TXA - Topical TXA | - | - | - | 0.995$ | |
| Knee (n = 6276) | |||||
| No TXA | 84 / 3581 | 2.3% | reference | ||
| With TXA | 33 / 2695 | 1.2% | 0.52 | 0.34–0.79 | 0.002 |
| IV TXA | 18 / 1568 | 1.1% | 0.49 | 0.29–0.83 | 0.008 |
| Topical TXA | 15 / 1127 | 1.3% | 0.56 | 0.32–0.98 | 0.042 |
| IV TXA - Topical TXA | - | 1.13 | 0.57–2.25 | 0.731 | |
$The model failed because of the small sample size
TXA, tranexamic acid; PJI, periprosthetic joint infection; OR: odds ratio; CI, confidence interval